Last update 29 Jun 2024

Dexamethasone

Last update 29 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryDexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging. The GR, which is widely distributed across various cell types, is responsible for myriad physiological responses, including immune and inflammatory responses. This small molecule drug, Dexamethasone, binds to the GR, which sends shockwaves of change through gene expression and protein synthesis, consequently giving inflammation and immune system activity a taste of their own medicine.When it comes to treating various conditions, Dexamethasone takes the crown. This potent drug has proved its mettle in treating an impressive range of conditions, including but not limited to actinic cheilitis, light chain (AL) amyloidosis, ocular inflammation, macular edema, and anaphylaxis. Back in the day, on October 30, 1958, the FDA gave the nod to Dexamethasone. It was a time when Merck & Co., Inc., a pharmaceutical company that hailed from the United States, hit the bull's eye with this innovative drug that promised a bright future.

Drug Type

Small molecule drug

Synonyms

Decadron Phosphate, Dexamethasone Intravitreal Implant, DEXTENZA

+ [46]

Target

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Immunoglobulin Light-Chain AmyloidosisOcular inflammationOphthalmologic surgical procedures+ [95]

Inactive Indication

Adult T-Cell Leukemia-LymphomaAdvanced Malignant Solid NeoplasmAggressive Non-Hodgkin Lymphoma+ [59]

Originator Organization

Merck & Co., Inc.

Active Organization

Ripple Therapeutics Corp.StartupOculis SA

Celgene Corp.

+ [43]

Inactive Organization

Fondazione IRCCS Policlinico San Matteo

Eli Lilly & Co.

GSK Plc

+ [44]

Drug Highest PhaseApproved

First Approval Date

US (30 Oct 1958),

AnaphylaxisEndocrine System DiseasesEye Diseases+ [7]

RegulationOrphan Drug (US), Priority Review (CN)

Structure

Molecular FormulaC22H29FO5

InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

CAS Registry50-02-2

3,915

Clinical Trials associated with Dexamethasone

NCT05521087 / Not yet recruitingPhase 1

A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 ([KMT2A1], nucleophosmin 1 gene (NPM1), or nucleoporin alterations in Part 1 (Dose Escalation) and to further evaluate safety at the RP2D(s) of JNJ-75276617 in combination with chemotherapy in pediatric and young adult participants with relapsed/refractory acute leukemia harboring KMT2A1, NPM1, or nucleoporin alterations and safety at the RP2D(s) of JNJ-75276617 as monotherapy in a select low burden of disease cohort in Part 2 (Dose Expansion).

Start Date26 Dec 2025

Sponsor / Collaborator

Janssen Research & Development LLC

NCT06207123 / Not yet recruitingPhase 1/2IIT

A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBL

The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.

Start Date01 Apr 2025

Sponsor / Collaborator

The University of Chicago

NCT06437054 / Not yet recruitingPhase 1/2IIT

Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)

This study is a prospective, randomized pilot study. To verify an efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.

Start Date15 Feb 2025

Sponsor / Collaborator

Seoul National University Hospital

100 Clinical Results associated with Dexamethasone

100 Translational Medicine associated with Dexamethasone

100 Patents (Medical) associated with Dexamethasone

59,814

Literatures (Medical) associated with Dexamethasone

31 Dec 2024·BioengineeredQ4 · BIOLOGY

Protective effects of ulinastatin on rats with acute lung injury induced by lipopolysaccharide

Q4 · BIOLOGY

ArticleOA

Author: He, Wei ; Lu, Qitong ; Liu, Zhiyong ; Chu, Xin

Qitong Lu, Zhiyong Liu, Wei He and Xin Chu. Protective effects of ulinastatin on rats with acute lung injury induced by lipopolysaccharide. Bioengineered. 2021 Oct. doi: 10.1080/21655979.2021.1987083.Since publication, significant concerns have been raised about the compliance with ethical policies for human research and the integrity of the data reported in the article.When approached for an explanation, the authors provided some original data but were not able to provide all the necessary supporting information. As verifying the validity of published work is core to the scholarly record's integrity, we are retracting the article. All authors listed in this publication have been informed.We have been informed in our decision-making by our editorial policies and the COPE guidelines. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted.'

31 Dec 2024·Hematology (Amsterdam, Netherlands)

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects

Review

Author: AlZahrani, Abdullah ; Alrajhi, Abdullah M ; Tailor, Imran K ; Alsuhebany, Nada

Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatment of chronic lymphocytic leukemia in April 2016 and later for acute myeloid leukemia in October 2020. However, venetoclax is used as an off-label in a subset group of relapsed and refractory multiple myeloma (RRMM) patients with the presence of translocation t(11;14). Preclinical and clinical studies have highlighted the potential of venetoclax in the management of MM patients, with a specific focus on t(11;14) as a predictive biomarker for initiating venetoclax-based treatment. Later, several studies in RRMM patients that used venetoclax in combination with dexamethasone or/and proteasome inhibitors have shown promising results, in which management guidelines have included venetoclax as one of the options to treat MM patients. Hence, this review focuses on the use of venetoclax in RRMM, clinical efficacy, safety, dosing strategies, and predictive biomarkers for initiating venetoclax. Additionally, we discuss ongoing studies that are investigating different combination of venetoclax regimens in MM patients.

31 Dec 2024·Animal cells and systems

Role of Carbohydrate response element-binding protein in mediating dexamethasone-induced glucose transporter 5 expression in Caco-2BBE cells and during the developmental phase in mice

Article

Author: Park, Sangbin ; Hwang, Soonjae ; Oh, Ah-Reum ; Kim, Jaewan ; Lee, Ho-Jae ; Cha, Ji-Young

Glucose transporter 5 (GLUT5), the main fructose transporter in mammals, is primarily responsible for absorbing dietary fructose in the small intestine. The expression of this intestinal gene significantly increases in response to developmental and dietary cues that reach the glucocorticoid receptor and carbohydrate response element-binding protein (ChREBP), respectively. Our study demonstrates that ChREBP is involved in the dexamethasone (Dex)-induced expression of GLUT5 in Caco-2BBE cells and the small intestine of both wild-type and ChREBP-knockout mice. Dex, a glucocorticoid, demonstrated an increase in GLUT5 mRNA levels in a dose- and time-dependent manner. While the overexpression of ChREBP moderately increased GLUT5 expression, its synergistic increase in the presence of Dex was noteworthy, whereas the suppression of ChREBP significantly reduced Dex-induced GLUT5 expression. Dex did not increase ChREBP protein levels but facilitated its nuclear translocation, thereby increasing the activity of the GLUT5 promoter. In vivo experiments conducted on 14-day-old mice pups treated with Dex for three days revealed that only wild-type mice (not ChREBP-knockout mice) exhibited Dex-mediated Glut5 gene induction, which further supports the role of ChREBP in regulating GLUT5 expression. Collectively, our results provide insights into the molecular mechanisms involved in the regulation of GLUT5 expression in response to developmental and dietary signals mediated by glucocorticoids and ChREBP. General significance: The transcription factor ChREBP is important for Dex-mediated Glut5 gene expression in the small intestine.

966

News (Medical) associated with Dexamethasone

27 Jun 2024

·www.prnewswire.com

American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 27, 2024 /PRNewswire/ -- USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising rates of cancer, the National Cancer Institute is making calls for change in how cancer clinical research is performed "Because our patients can't wait." According to Spherical Insights, the Global Oncology Drugs Market is projected to grow by 11.5% CAGR through 2033 to US$564.5 billion, highlighting the need for more effective therapies and incentives for those who develop them. The biotech sector is actively addressing this need, with recent notable developments from several companies, including: O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), GSK plc (NYSE: GSK), Guardant Health, Inc. (NASDAQ: GH), Exelixis, Inc. (NASDAQ: EXEL), and Gilead Sciences, Inc. (NASDAQ: GILD). The article continued: According to the World Health Organization, the global cancer burden is growing amidst a mounting need for services. As well, an alarming trend is emerging, where cancer cases in younger people are rising sharply. Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy. "Aligning with the FDA on key design elements and objectives of our planned registrational trial for pelareorep marks a critical step towards bringing this innovative treatment to patients," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. "Our de-risked program builds on compelling data and key learnings from two randomized studies, BRACELET-1 and IND-213, which demonstrated clinically meaningful benefit in patients receiving pelareorep and paclitaxel compared to paclitaxel alone. Additionally, translational data from the AWARE-1 study highlights pelareorep's immune-mediated mechanism of action in breast cancer patients. We are now well-positioned to deliver on our mission of making pelareorep available to breast cancer patients in need of better treatment options." Wayne Pisano, Interim CEO and Chair of the Board of Oncolytics, commented, "We are appreciative of the thoughtful dialog with the FDA and are pleased to have reached an important regulatory milestone that provides a clear path forward for pelareorep's advancement towards registration in HR+/HER2- mBC. Looking ahead, initiating a registration-enabling trial has become a major corporate objective, and in parallel, we remain on track to report survival data from the BRACELET-1 study in HR+/HER2- mBC in the second half of the year. We believe these data will further bolster our compelling data package and underscores the therapeutic potential of pelareorep. We remain committed to improving the standard of care and addressing the high unmet medical needs of these patients." CONTINUED… Read this and more news for Oncolytics Biotech at: In other industry developments and happenings in the market this week include: GSK plc (NYSE: GSK), a global biopharma company, recently released positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating belantamab mafodotin, in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma. As per the release, the drug combination reduced the risk of disease progression or death by nearly 50% versus standard of care. "With the robust results from the DREAMM-8 phase III head-to-head trial, we now have consistent data from two phase III trials supporting the potential for belantamab mafodotin combinations to redefine the treatment of multiple myeloma at or after first relapse," said Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, of GSK. "This is exciting news given the high unmet need for new and efficacious combinations once patients relapse or stop responding to initial treatments. We continue to share data and discuss our path forward with regulators." Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, recently announced the launch of a new version of its Guardant360 TissueNext test that expanded the number of genes it identifies in a tumor tissue sample to 498. In addition to the panel expansion, Guardant has improved the test's operational workflow for a faster turnaround time. "The launch of the new Guardant360 TissueNext test is another step forward in our mission to conquer cancer with data," said Helmy Eltouky, Chairman and co-CEO of Guardant Health. "In addition to identifying guideline-recommended biomarkers, the upgraded test now provides more comprehensive gene coverage, so oncologists can make better informed decisions about the optimal treatment strategy for their patients with advanced cancer and help improve their outcomes." Exelixis, Inc. (NASDAQ: EXEL), a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care, recently settled two patent litigations with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla) in response to Cipla's Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. Prior to the settlement earlier this year, Exelixis also announced detailed results of its Phase 3 CONTACT-02 pivotal trial evaluating the above-mentioned cabozantinib in combination with atezolizumab in metastatic castration-resistant prostate cancer at this year's ASCO GU 2024 event. As per the results, the combination reduced the risk of disease progression or death by 35%. "Given there are limited options after progression on novel hormonal therapy, we recognize the need for a regimen that can delay disease progression, that has an acceptable tolerability profile and that is widely available to patients who may not have the means or desire to travel to specialized centers for other therapies," said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. "We look forward to discussing these important results with the U.S. Food and Drug Administration, and to learning more in the next analysis of overall survival, anticipated this year." Through its recently-acquired Kite subsidiary, Gilead Sciences, Inc. (NASDAQ: GILD) recently announced results from three new analyses for Yescarta (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid. "We are committed to improving survival outcomes for people living with difficult-to-treat blood cancers," said Ibrahim Elhoussieny, Vice President, Medical Affairs, of Kite. "These new data support the potential benefit of utilizing Yescarta in earlier lines of treatment, both in terms of manufacturing success and product characteristics. Additional data support the safety and feasibility of administering CAR T-cell therapy in the outpatient setting. These data contribute to the body of evidence for efficient utilization and delivery of Yescarta and Tecartus and further support our ambition for patients." Source: CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCE USA News Group

Phase 3Clinical ResultImmunotherapy

27 Jun 2024

·pipelinereview.com

Oncopeptides selects first candidate drug from its SPiKE platform

STOCKHOLM, Sweden I June 27, 2024 I Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected. The SPiKE platform uses multi-specific constructs, able to bind to multiple targets simultaneously. The first drug candidate, OPSP1, is a bi-specific construct designed to both engage natural killer cells, a type of immune cell, and target cancer cells. The goal of OPSP1 is to prove the ability of the SPiKE platform to activate these natural killer cells. To do this, OPSP1 targets a specific protein called BCMA that is expressed in some cancers including multiple myeloma. By targeting this protein, Oncopeptides will be able to assess how well the SPiKE platform can activate natural killer cells to fight cancer, a crucial step before continued clinical development of the SPiKE platform. “There is significant potential in NK cell-mediated therapy for difficult-to-treat cancers,” says Dr. Karl-Johan Malmberg, professor at Oslo University and Karolinska Institutet. ”Despite the substantial advancements in current treatments, the reality is that resistance to these therapies often develops. This underscores the urgent need for new and innovative treatment options to address this unmet medical need.” NK cell-mediated therapy represents a promising avenue in cancer immunotherapy, with ongoing research aimed at overcoming existing challenges and enhancing its therapeutic potential. As a next step for Oncopeptides, a first-in-human clinical trial will be designed to evaluate the safety, efficacy, and overall therapeutic potential of OPSP1. “The ability to show a promising product pipeline behind its flagship product is important for a growing biotech company. Following the accomplishments we have seen with our first technology platform PDC, where we have an approved product, we are excited to also announce progress with SPiKE, our second technology platform,” says Sofia Heigis, CEO of Oncopeptides. “This milestone is a major step forward in our ambition to ensure that Oncopeptides can continue to provide hope for patients suffering from difficult-to-treat cancers, and value to shareholders investing in our science.” A pre-clinical project for the SPiKE platform has received a financial grant from the Eurostars 3-program, co-financed by the European Union research and innovation program “Horizon Europe” and is driven by an international research consortium that includes world-leading expertise from the department of Cancer Immunology at Oslo University Hospital, Pharmatest Services Ltd in Turku, Finland and the Royal Institute of Technology in Stockholm (KTH), from where the technology originally stems. With this grant, Sweden’s Innovation Agency, Vinnova, has provided Oncopeptides resources to develop pre-clinical proof of concept for a novel synthetic small polypeptide for the treatment of multiple myeloma. For more information, including questions and answers for investors and additional details on the SPiKE platform, please visit our website . About Oncopeptides Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com SOURCE: Oncopeptides

Clinical StudyDrug ApprovalImmunotherapyPDC

27 Jun 2024

·www.biospace.com

Oculis and EURETINA Announces the Ramin Tadayoni Award

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award. In memory of the Company’s Chief Scientific Officer and a world-renowned retina specialist, EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has established the Ramin Tadayoni Award supported by Oculis. This annual award of €30,000 for research support, with an additional €5,000 for the candidate, will recognise the future generation of talented ophthalmologists who have demonstrated outstanding potential in the field of retina research. Applications will be accepted in June and July 2024, and the first award will be granted at the EURETINA Congress in September. “Prof. Ramin Tadayoni was an exceptional friend and a highly accomplished and world-renowned retina specialist that, as an advisor, played a key part in Oculis progress since its inception, and most recently as its Chief Scientific Officer,” said Riad Sherif M.D., Chief Executive Officer of Oculis. “He was truly a luminary in the field of ophthalmology and, in addition to his scientific achievements, he is remembered for his kindness, mentorship and unwavering commitment to advancing the field and bettering patients’ lives. Prof. Tadayoni has left behind a profound legacy and we are very pleased that this award will carry forward his dedication to high quality research in the field of retina, to education, and to patients suffering from blinding diseases.” “The Ramin Tadayoni Award has been established to honour the memory of a remarkable individual whose contributions significantly advanced ophthalmic disease research. This initiative serves both as a legacy to an incredible man and a tribute to his work. By preserving the contributions of Prof. Tadayoni, we are also investing in the future generation of brilliant ophthalmologists who will drive research excellence and innovation in retinal care. We are proud to launch this prestigious award in tribute to a visionary leader and cherished friend. We are most grateful to Oculis for its support of the initiative," said Anat, Loewenstein, M.D., President of EURETINA. Prof. Tadayoni was appointed as Chief Scientific Officer of Oculis in February 2024. At the time, he served as the President of EURETINA, the European Society of Retina Specialists and the Retina Department Chairman of Rothschild Foundation Hospital, including the French Myopia Institute. Prior, he was also Chief of the Department for Lariboisière university hospitals and Saint-Louis hospital and Professor of Ophthalmology at University Paris-Cité. Prof. Tadayoni was a Principal Investigator in numerous trials and served as an advisor for companies in the ophthalmology space for over two decades, including his role as Chair of the Oculis’ Retina Scientific Advisory Board. He was a passionate physician and researcher, authoring over 320 medical and scientific articles and making numerous contributions to ophthalmology textbooks. He was the recipient of numerous awards, including the American Academy of Ophthalmology Achievement Award and the prestigious Jules Gonin Award from the Retina Research Foundation. Dr. Tadayoni completed his medical degree and internship at Paris V University. His retina fellowship was completed at Lariboisière University Hospital while simultaneously pursuing his Ph.D. in Science at Paris VII University and the Paris Vision Institute. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02, a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: Oculis Contacts Ms. Sylvia Cheung, CFO sylvia.cheung@oculis.com Investor & Media Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com 1-212-915-2577

Executive Change

100 Deals associated with Dexamethasone

External Link

KEGG	Wiki	ATC	Drug Bank
D00292	Dexamethasone	D07AB19 H02AB02 D10AA03	DB01234

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Immunoglobulin Light-Chain Amyloidosis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	25 Aug 2021
Ocular inflammation	US	Ocular Therapeutix, Inc.	30 Nov 2018
Ophthalmologic surgical procedures	US	Ocular Therapeutix, Inc.	30 Nov 2018
Post procedural inflammation	US	EyePoint Pharmaceuticals, Inc.	09 Feb 2018
Diabetic macular oedema	EU	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	IS	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	LI	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	NO	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Macular Edema	EU	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Macular Edema	IS	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Macular Edema	LI	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Macular Edema	NO	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	EU	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	IS	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	LI	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	NO	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Multiple Myeloma	JP	Bristol Myers Squibb Co.	18 Jun 2010
Retinal Vein Occlusion	US	AbbVie, Inc.	17 Jun 2009
Nausea and vomiting	JP	Nichi-Iko Pharmaceutical Co., Ltd.	15 Sep 2005
Blepharitis	JP	Santen Pharmaceutical Co., Ltd.	03 Feb 1970

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	NDA/BLA	SG	AffaMed Therapeutics	19 Feb 2024
Hospital-acquired pneumonia	Phase 3	FR	Nantes University Hospital	15 Feb 2024
Pain	Phase 3	CN	Ocular Therapeutix, Inc.	17 Aug 2023
Pain	Phase 3	CN	AffaMed Therapeutics	17 Aug 2023
Inflammation	Phase 3	US	Ocular Therapeutix, Inc.	04 Sep 2020
Severe Acute Respiratory Syndrome	Phase 3	GM	University of Oxford	19 Mar 2020
Severe Acute Respiratory Syndrome	Phase 3	ZA	University of Oxford	19 Mar 2020
Severe Acute Respiratory Syndrome	Phase 3	GB	University of Oxford	19 Mar 2020
Breast Cancer	Phase 3	US	National Cancer Institute	19 Apr 2018
NK-cell lymphoma	Phase 3	HK	University of Hong Kong	01 Jul 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DRKS00010738 (Literature) Manual	Phase 2/3	Hearing Loss, Sudden	-	prednisolone 250 mg/d (HD-Pred)	xsowitgyrz(rchqgcxcls) = okhmbfigof tnlmdzmkhz (vsfuouqbqk, 28.4 ~ 40.0)	Negative	26 Dec 2024
				dexamethasone 40 mg/d (HD-Dex)	xsowitgyrz(rchqgcxcls) = mfywjewpyf tnlmdzmkhz (vsfuouqbqk, 35.6 ~ 47.2)
NCT04037462 (CTgov)	Phase 1/2	Non-Small Cell Lung Cancer	2	Dexamthasone	hwemewmjde(vkgwccifyz) = ysfmrcpsvs imlphmjfpx (ajucsrjadv, dneifxubkn - busvzcbily) View more	-	14 Jun 2024
NCT05480111 (CTgov)	Phase 4	Pain, Postoperative	76	Sham QL+Local anesthesia at incision site (Local Anesthesia at Incision Site)	kszutidbta(ercjkrprrc) = ytmncqpqju ihbfpkayih (mowacbamsc, dqnvuskfss - dbxyuqpyvr) View more	-	05 Jun 2024
				QL (QL Block)	kszutidbta(ercjkrprrc) = qvhevtyrkw ihbfpkayih (mowacbamsc, piozxscjfu - vlcasmskoc) View more
NCT01277289 (CTgov)	Phase 3	Crohn Disease	51	Dexamethasone (Ery-dex)	lfxyowzxnf(nwaoqiffrx) = uimxetvuaj ytqsmhcwqb (rloivnjhjo, klmmickxhl - wxeslnokzn) View more	-	03 Jun 2024
				Dexamethasone (Placebo)	lfxyowzxnf(nwaoqiffrx) = otjgcnvnqp ytqsmhcwqb (rloivnjhjo, umkgfylczh - cywjrkylqj) View more
NCT03374085 (CC-92480-MM-001, ASCO2024) Manual	Phase 1/2	Relapse multiple myeloma \| Plasma cell myeloma refractory \| Renal Insufficiency	101	mezigdomide + dexamethasone	prhnizntre(fjmpcerpkd) = mmnhamkmym sfkrdrathl (vwokrcpxlp ) View more	Positive	24 May 2024
				mezigdomide + dexamethasone (No RI)	prhnizntre(fjmpcerpkd) = eqzpigzjsz sfkrdrathl (vwokrcpxlp ) View more
NCT03319667 (IMROZ, ASCO2024) Manual	Phase 3	Multiple Myeloma First line anti-CD38 monoclonal antibody	446	Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd)	drepqjnkpk(swuzfdoyfk) = brsxoyxxlg utbkfhmwak (uyhezzeihl, 0.406 - 0.876) View more	Positive	24 May 2024
				bortezomib, lenalidomide, and dexamethasone(VRd)	drepqjnkpk(swuzfdoyfk) = vqkrockxls utbkfhmwak (uyhezzeihl ) View more
NCT03710603 (PERSEUS, ASCO2024)	Phase 3	Multiple Myeloma Maintenance	709	DARA SC + VRd (D-VRd)	fkbpoitcio(ozxtdrimse) = esepwkioom tdcrlrqmdj (rssxwlxdhp ) View more	Positive	24 May 2024
				VRd	fkbpoitcio(ozxtdrimse) = efolvmmeoh tdcrlrqmdj (rssxwlxdhp ) View more
ASCO2024	Not Applicable	Multiple Myeloma	-	Branded 20 mg dexamethasone tablets (BDex)	rahvywyvfy(cndbhfheuj) = dvmyujatsb iqahvhqqdz (cnemijhtbk )	Positive	24 May 2024
				Generic 4 mg dexamethasone (GDex)	rahvywyvfy(cndbhfheuj) = fhafhbljzd iqahvhqqdz (cnemijhtbk )
NCT04156581 (CTgov)	Phase 4	Pain, Postoperative	46	Dexamethasone+bupivacaine (ESPB With Bupivacaine and Dexamethasone)	tsjiaikixr(aofngugmuz) = aqsqmylpil tbwexkxfhb (oqrbdvptso, ltjadnjhtc - uqurktarpm) View more	-	24 May 2024
				Saline (ESPB With Saline Placebo)	tsjiaikixr(aofngugmuz) = jyszwahsmy tbwexkxfhb (oqrbdvptso, actnqjmdxx - tigosnvxne) View more
NCT03457142 (CTgov)	Phase 2	Recurrent Multiple Myeloma \| Plasma cell myeloma refractory	15	Laboratory Biomarker Analysis+Abatacept+Ixazomib Citrate+Dexamethasone	ytemjvyrfo(ajctuubckj) = rkfjehtdjj ckxyyvvumo (wyewacxftm, passngvthk - mgdmewbsml) View more	-	16 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis